SCHEMBL24136296

SCHEMBL24136296

CCOCCOCCOCCOCCOCCOCCOCCNC(=O)CCN1C(=O)CC(C(C)C)C1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.37
POLB P06746 1/20 0.37
HSD17B10 Q99714 1/20 0.37
SLC9A3 P48764 3/20 0.37
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
HDAC3 O15379 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC7 Q8WUI4 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC10 Q969S8 1/20 0.35
HDAC11 Q96DB2 1/20 0.35
HDAC8 Q9BY41 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15627255 1.00 SMN1; SMN2 (0.37) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL27306806 0.93 SMN1; SMN2 (0.37) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL16118174 0.92 SMN1; SMN2 (0.38) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL24136297 0.91 SMN1; SMN2 (0.47) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL14750406 0.90 SMN1; SMN2 (0.39) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL22134362 0.90 SMN1; SMN2 (0.37) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL18430819 0.89 SMN1; SMN2 (0.35) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL25100591 0.89 SMN1; SMN2 (0.51) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL14750411 0.89 SMN1; SMN2 (0.36) SMN1; SMN2HPGDHTTPOLBHSD17B10
SCHEMBL22134405 0.89 DRD2 (0.37) SMN1; SMN2HPGDHTTPOLBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11208451-B2 Protein and protein conjugate for diabetes treatment, and applications thereof ADDA BIOTECH INC. 2021-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11208451-B2 Protein and protein conjugate for diabetes treatment, and applications thereof GLP1R, GIPR, IAPP SMN1; SMN2 2613/4885HPGD 3590/4885HTT 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.